Biofrontera Inc.
BFRIHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The $11.7M market capitalization puts BFRI squarely in micro-cap range for its industry. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Market Cap
$11.7M
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
1.84
EPS (TTM)
$-0.43
EPS (Fwd)
$0.43
ROE
-988.4%
ROA
-17.4%
Cash
$4.7M
Total Debt
$7.5M
Free CF
-$7.6M
52W Change
-28.3%
Annual Financials
Cash vs Debt
Where BFRI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BFRI finished 25.69% below its 150-day moving average ($1.09) and 21.36% below its 200-day moving average ($1.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BFRI overbought or oversold?
At the October 20, 2026 close, BFRI's RSI(14) was 22.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $4.7M in cash, though total debt stands at $7.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$7.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -988.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $28.7M (2022) to $41.7M (2025), reflecting a 45% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Biofrontera Inc.'s trajectory.